The Center for Innovative Technology (CIT) https://www.cit.org has announced that CIT GAP Funds https://www.citgapfunds.org have invested in Jeeva Informatics Solutions, https://www.jeevatrials.com, a precision medicine data science company.
The company is focused on significantly accelerating clinical trial operations by taking trials to patients’ homes. Jeeva’s goal is in to replace 20% to 80% of brick and mortar site visits for participants with centrally coordinated eVisits.
CIT GAP Funds makes seed stage equity investments in Virginia-based technology with life science companies that show a high potential for achieving rapid growth and generating significant economic return for entrepreneurs, co-investors, and the Commonwealth of Virginia
Using AI and digital health technologies, Jeeva is able to fast track patient recruitment for clinical trials, improve adherence to trial protocols, and reduce patient burden and dropout rates. These are some of the challenges in bringing innovative medicine to market. Plans are to use the funds to advance customer pilot projects and use cases for further validation.
Traditional clinical trial processes have been inefficient and fairly unchanged for decades, with only 12% of all candidate drugs entering clinical trial phases ever receiving FDA approvals. Patient recruitment continues to be the biggest hurdle in the biopharma clinical trial process, as most patients have to travel to brick and mortar sites. Nearly 30% of consented patients are likely to drop out before the trial is completed.
According to Harsha Rajasimha CEO of Jeeva, “We believe that access to critical therapies should not be a function of the patient’s zip code. Our solution enables communities in rural, communities to participate in late stage clinical trials.”
The company is actively discussing pilot projects with clinical researchers interested in post-market real world evidence studies, cohort studies, and gene therapy trials. Jeeva has delivered biohealthIT solutions to Catholic initiatives, Morehouse School of Medicine, and Lockheed Martin.